Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380306 | 0.80 | OPRD1 (0.39) | SLC6A9OPRK1 | |
| SCHEMBL632289 | 0.73 | SLC6A9 (0.38) | SLC6A9OPRK1 | |
| SCHEMBL381012 | 0.68 | OPRM1 (0.41) | CHRM2CHRM4CHRM5SIGMAR1OPRK1 | |
| SCHEMBL3706694 | 0.67 | OPRD1 (0.38) | SLC6A9OPRK1 | |
| SCHEMBL4184268 | 0.67 | OPRD1 (0.38) | SLC6A9OPRK1 | |
| SCHEMBL381169 | 0.67 | BCHE (0.40) | CHRM2CHRM4CHRM5OPRK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4184756 | 0.66 | OPRD1 (0.37) | SLC6A9SIGMAR1OPRK1 | |
| SCHEMBL381170 | 0.65 | OPRK1 (0.35) | CHRM2CHRM4CHRM5SIGMAR1OPRK1 | |
| SCHEMBL21848108 | 0.64 | FUCA1 (0.50) | TACR1SIGMAR1FUCA1 | |
| SCHEMBL4186582 | 0.64 | SLC6A9 (0.51) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071536-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-22 | — | — | US | disclosed |
| EP-2408763-A2 | DERIVATIVES OF N-Ý(2-AZA-BICYCLOÝ2.1.1¨HEX-1-YL)-ARYL-METHYL¨-HETEROBENZAMIDE, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| EP-2396334-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL]-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010106269-A2 | DERIVATIVES OF N-[(2-AZA-BICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-HETEROBENZAMIDE, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010092286-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL]-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071536-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | HRH4, NT5C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A9 3512/4885TACR1 37/4885CHRM2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.